Best Practices for Tapering off of Benzodiazepines

For those affected by benzodiazepine withdrawal syndrome (BZWS), deprescription is a complex process. This analysis and tutorial address only the mechanics and problems of BZD dose reduction. Prior to reading this, you should be familiar with the information contained in Pamphlet 3 – BZRA Discontinuation 1 - Getting Started. Once you are familiar with the best practices for the benzodiazepines tapering process presented in Pamphlet 3, you can complete your understanding of the entire benzodiazepine deprescription process by reading these pamphlets:

Pamphlet 4 - BZRA Discontinuation 2 - Symptomatic Relief
Pamphlet 5 - BZRA Discontinuation 3 - Completion and Repair
Pamphlet 6 - BZRA Discontinuation 4 - It Takes a Team

Note that the term “BZRA” includes both BZDs and Z-drugs.

Contents

1. Benzodiazepine De-prescription is Different
   1.1 “Right sized” dosage changes are required
   1.2 “Therapeutic dose” is not useful during deprescription

2. The Four Parts of a Typical BZD Taper
   2.1 Part 1: Substitute a long-acting BZD
   2.2 Part 2: Coarse taper
   2.3 Part 3: Fine taper
   2.4 Part 4A: Ultrafine taper
   2.5 Part 4B: “Kitchen Chemistry” ultrafine taper

Table 1: Benzodiazepine Dosages, Solutions and Suspensions [6,7,8]
Table 2: Benzodiazepine Solubilities [3,4,5,6]

3. Sample Tapers

4. References

5. Other BZD Compounding References

Disclaimer: This pamphlet does not provide patient medical advice. It is provided for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
1. Benzodiazepine De-prescription is Different

Unlike the method commonly practiced for most other medications, most benzodiazepine deprescribing requires a cyclic tapering process with long taper periods and small dosage reductions.[1] As shown in figure 1, this includes multiple monitoring and adjustment steps in addition to the planned dosage reductions common to other medication classes. The benzodiazepine deprescription cycle has several key attributes.

1.1 “Right sized” dosage changes are required

When tapering a patient off of benzodiazepines, periodic monitoring and adjustments to the size of dosage reductions are usually required. Note that the percentage decreases need to be measured relative to the previous dosage, and not relative to the dosage at the start of the taper. A 10% dosage reduction near the end of a benzodiazepine taper may need to be 10 times smaller than a 10% dosage reduction at the start of the taper. Unlike the standard medical school deprescription model, this cyclic process is not linear, and yields a deprescription curve similar to what can be seen in figure 2.

At the initiation of a taper, depending on the dosages available for the benzodiazepine being tapered and the desired rate of taper at the time, it may be possible to use lower dosage pills or pill cutting. However, this method may not be possible with those who require a very gradual taper. In such a case, a combination of whole pill(s) and fine or ultrafine tapering may be required. Note that pill cutting is usually too coarse for later reductions.

1.2 “Therapeutic dose” is not useful during deprescription

The minimal therapeutic dose cannot be used to reliably guide dosage reductions of benzodiazepines. For a surprisingly large percentage of patients, reductions in dosage in the sub-therapeutic range can elicit a significant increase in BZWS symptoms.[2] Even relatively small dosage reductions (e.g., 10%) when the current dose is near or below the minimal therapeutic dose may be intolerable or require long recovery times.
2. The Four Parts of a Typical BZD Taper

For all BZRAs (which includes the Z-drugs), and especially for benzodiazepines, a “typical” taper will consist of up to four parts. For a given patient, it may be possible to skip one or more parts.

Precautions for all parts of a taper

1. Although it is difficult to obtain data on drug manufacturers’ quality, pharmaceutical manufacturing standards allow BZD strength to vary by +/- 15% between tablets.[3] While this high variability is unlikely within a given lot, it is possible between different lots, and even more likely between different manufacturers. This possible 30% variability is often overlooked, and can be a significant effect for the susceptible patient. The best practice is to stay with the same manufacturer throughout the taper and treat the transition to a new lot number of a given BZD like a dosage reduction, allowing equal settling time as provided for a dosage reduction. A riskier alternative is to make this transition midway between dosage reductions. Transitioning at the same time as making a dosage reduction should be avoided.

2. BZWS patients are often both psychologically and physically compromised, and have difficulty following complex sequential instructions. Given the highly varying nature of benzodiazepine withdrawal symptoms over time for a given patient, it is very important to provide clear, unambiguous instructions.

3. Because it is not safe to alter any kind of modified-release tablets, extended-release BZD formulations are inappropriate for tapering.

2.1 Part 1: Substitute a long-acting BZD

In general, it has been shown that it is easier to de-prescribe a patient from a benzodiazepine with a longer half-life than from one with a shorter half-life.[4] Problems with inter-dose withdrawal are reduced, and the effects of a given dosage reduction are amortized over a longer period of time. Note that this is an optional step, and it can be done at any time. Substitution is based on BZD equivalency tables or calculators. Click HERE for a comparison of benzodiazepine equivalencies using two different calculators.

Note that the proper dose equivalency is one at which the patient is feeling relatively stable after the transition. Many patients can taper directly off their current benzodiazepine. Since this is much simpler and avoids the sometimes lengthy transition time to a longer-acting BZD, it should be the first choice in these cases. It is recommended that the patient should be transitioned to a long-acting BZD only if the patient is having difficulty with their short-acting BZD. When substitution is indicated, diazepam is most commonly recommended, since it has a long half-life and is available in a wide range of strengths and solutions.

Precautions for substitution

1. Regardless of the claims of any given source, equivalencies are ranges, and are not exact.[5] These ranges can vary by as much as 2x, which can make substitution very inexact and potentially risky for some benzodiazepines.

Preliminary Information – Subject to Change

Disclaimer: This pamphlet does not provide patient medical advice. It is provided for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
2. Depending on the patient and the benzodiazepines involved, substitution can add 1-4 weeks to a taper.
3. Some patients may find substitution intolerable, whether due to the differing pharmacokinetics or the equivalency ambiguities of the two benzodiazepines.

2.2 Part 2: Coarse taper

This part of deprescription consists of tapering by reducing the number of pills, using pills of reduced dosage, cutting pills, or some combination of these methods. The coarse taper part of deprescription needs to meet all of the requirements for safe BZD deprescription, and this typically limits its applicability to patients who are taking relatively high doses. A coarse taper has the advantages of being more familiar and relatively easy to implement. It can be used until it is no longer viable due to the physical limitations of cutting pills.

For more susceptible individuals, a coarse taper is commonly combined with the fine or ultrafine taper methods to achieve a slower taper rate.

Precautions for coarse taper

1. There is no guarantee of BZD homogeneity within a pill. For most medications, this risk is usually ignored. For the sensitive BZD patient using cut pills, it may be significant.
2. Many BZDs are not scored for cutting, and none are scored for cuts below ½. Patients need to be made aware that pills must be cut precisely, especially at the ¼-pill level, where it is difficult to be precise. This is particularly important where the BZD being tapered has a short half-life, and the imprecision is not amortized over several doses.
3. Cuts below ¼ of a pill are not recommended.

2.3 Part 3: Fine taper

A slower rate of taper can be achieved by using an oral solution, such as one of the Intensol solutions available for most of the BZDs, along with a finely graduated syringe. Note that this method is only viable until the dose becomes so small that it induces handling problems. See table 1 below for the recommended minimum dosage levels using these solutions.

Precautions for fine taper

1. Intensol solutions are not available for all BZDs prescribed in the US. See table 1 for availability.
2. Since a fine taper uses a solution, it requires multi-step patient instruction and demonstration of competent use of a graduated syringe.
3. A taper using an oral solution requires precision. This is especially true at lower doses, where an imprecise measurement can result in a significant deviation from the desired percentage of dosage reduction.
4. One disadvantage to this method is its complexity. Patients may need extra support.

2.4 Part 4A: Ultrafine taper

For some patients, a very small change in dosage can result in significant exacerbation of withdrawal symptoms. While there is no rigorously controlled research on this topic, substantial anecdotal evidence shows that this may be quite widespread, possibly affecting 10% those undergoing BZD withdrawal. Additionally, as noted above, the Intensol solutions used in a fine taper are not available for all BZDs. In these cases, the use of a compounded formulation is recommended. Compounded formulations can be made of any BZD, and they allow finer dosage reductions than possible with non-compounded formulations. Diazepam, alprazolam, lorazepam and clonazepam are available as stability-tested compounded formulas (see table 1).

Precautions for ultrafine taper

1. Some BZDs do not have an USP compounding formula.
2. The patient may not have access to a compounding pharmacy.
3. Compounded formulations are usually more expensive. In addition, some insurance companies either do not cover compounded medications or only partially cover their cost.

2.5 Part 4B: “Kitchen Chemistry” ultrafine taper

It is important for the clinician to know that their patient may be aware of the availability of many “kitchen chemistry” methods for achieving an ultrafine BZD taper. These include many formulas, videos and other how-to instructional media on the internet.

A. The least risky “kitchen chemistry” method is the Suspension Method, which is as follows:
   1. Pulverize a whole tablet, or place it a measured (small) amount of water and wait until it disintegrates.
   2. Thoroughly mix it in a measured amount of a USP grade suspension vehicle (such as Humco FlavorBlend™ or Specialized Rx SuspendRx™ Anhydrous Base, available online or from a compounding pharmacy).
   3. Withdraw a measured amount of the suspended mix and discard it.
   4. Consume the remaining suspension.

B. The most readily available “kitchen chemistry” method is the Agitation Method, which is as follows:
   1. Prepare the tablet as in A.1. above.
   2. Mix it for at least 10 seconds with a measured amount of water.
   3. While it is being vigorously stirred, withdraw a measured amount of the mixture and discard it. Active agitation during this step is essential.
   4. Consume the remaining mixture.
C. Another commonly used “kitchen chemistry” method is the Scale Method, which is as follows:
1. Acquire and calibrate a milligram-capable scale.
2. Weigh a whole tablet.
3. Calculate the weight required to produce the desired dosage reduction.
4. Remove part of the tablet until the desired weight is obtained. A fine abrasive instrument, such as a nail file, is commonly used for fine adjustments.
5. Consume the remaining tablet.

Precautions for “kitchen chemistry” ultrafine taper
1. None of the methods or formulas have undergone systematic review. A sampling shows that they range from risky to harmful. None of these methods are recommended.
2. The Suspension Method is the least risky, yet it is imprecise.
3. Although BZDs have only a very small solubility in water (see Table 2 below), the Agitation Method uses water. This leads to unpredictable dispersion of the BZD. Some methods use ethyl alcohol, which has its own set of problems and interferes with BZD action, and should be avoided.

Table 1: Benzodiazepine Dosages, Solutions and Suspensions [6,7,8]

<table>
<thead>
<tr>
<th>Benzo-diazepine</th>
<th>Pill Dosages (mg)</th>
<th>Solution</th>
<th>USP Compounded Formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Type</td>
<td>Strength (mg/ml)</td>
</tr>
<tr>
<td>Alprazolam</td>
<td>3*, 2, 1, 0.5, 0.25</td>
<td>Intensol</td>
<td>1</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>2, 1, 0.5, 0.25, 0.125</td>
<td>Liquid oral ***</td>
<td>0.1, 0.2, 0.4</td>
</tr>
<tr>
<td>Diazepam</td>
<td>10, 5, 2</td>
<td>Intensol</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Liquid oral</td>
<td>1</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>2, 1, 0.5</td>
<td>Intensol</td>
<td>2</td>
</tr>
<tr>
<td>Temazepam</td>
<td>30, 22.5, 15, 7.5</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

* Not available in the US
*** Available via specialty pharmacies in the UK, but not available in the US.

Disclaimer: This pamphlet does not provide patient medical advice. It is provided for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
### Table 2: Benzodiazepine Solubilities [3,4,5,6]

<table>
<thead>
<tr>
<th>Benzo-diazepine</th>
<th>Solubility (mg/ml)</th>
<th>Stability</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Water</td>
<td>Ethanol</td>
</tr>
<tr>
<td>Alprazolam</td>
<td>0</td>
<td>Yes*</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>0.1</td>
<td>?@90% alcohol/water</td>
</tr>
<tr>
<td>Diazepam</td>
<td>0.05</td>
<td>62.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lorazepam</td>
<td>0.08</td>
<td>14</td>
</tr>
<tr>
<td>Temazepam</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* per label, but no actual solubility listed

---

**Preliminary Information – Subject to Change**

**Disclaimer:** This pamphlet does not provide patient medical advice. It is provided for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
3. Sample Tapers

Patient-led benzodiazepine tapers are highly variable. Here are two examples: one a moderate-difficulty taper, and the other a severe case. These are presented to demonstrate the principles used in benzodiazepine tapers, but they also illustrate how pre-set tapering schedules do not meet the needs of the benzodiazepine-dependent patient. For brevity, dosage reductions are referred to as “cuts”.

Example 1: Clonazepam, higher dose, moderate case
Patient taking 2 mg clonazepam three times per day for 5 years. Baseline symptoms and severity noted. Patient asks for fast taper, but wants to minimize symptoms.

Day 1: Make first cut, to 1.75 mg tid (12.5%)
Day 2: Check: No significant increase in symptoms. Baseline taper amount established (0.25 mg).
Day 14: Make 2nd cut, to 1.5 mg tid (14.2%) Baseline inter-cut duration set (2 weeks)
Week 4: Significant symptoms noted. Hold for extra week, decrease cuts to 0.125 mg
Week 5: Make 3rd cut, to 1.375 mg tid (8.3%)
Week 7: Make 4th cut, to 1.25 mg tid (9.1%)
...
Week 15: Make 8th cut, to 0.75 mg tid (14.3%)  
Week 17: Significant symptoms noted. Hold for extra week, decrease cuts to once per day, 1 week duration
Week 18: Symptoms return to baseline. Make 9th cut, to 0.625 mg AM, 0.75 mg mid-day, and 0.75 mg PM (5.6%)
Week 19: Make 10th cut, to 0.625 mg AM, 0.625 mg mid, and 0.75 mg PM (5.9%)
...
Week 25: Make 16th cut, to 0.375 mg AM, 0.375 mg mid, and 0.5 mg PM (9.1%)
Week 26: Significant symptoms noted. Hold for extra week, increase duration to 2 weeks
Week 27: Symptoms return to baseline. Make 17th cut, to 0.375 / 0.375 / 0.375 mg (9.1%)
Week 29: Make 18th cut, to 0.25 / 0.375 / 0.375 mg (10%)
...
Week 35: Make 21st cut, to 0.125 / 0.25 / 0.25 mg (16.7%)
Week 37: Significant symptoms noted. Hold for extra week, decrease cut to 0.062 mg (1/2 of a 0.125 tablet)
Week 38: Symptoms return to baseline. Make 22nd cut, to 0.125 / 0.188 / 0.25 mg (9.9%)
Week 39: Make 23rd cut, to 0.125 / 0.188 / 0.188 mg (11.1%)
...
Week 45: Make 26th cut, to 0.062 / 0.125 / 0.125 mg (16.5%)
Week 47: Significant symptoms noted. Hold for extra week
Week 49: Symptoms return to baseline. Make 27th cut, to 0.062 / 0.062 / 0.125 mg (20%)
Week 51: Significant symptoms noted. Hold for extra week
Week 52: Symptoms return to baseline. Make 28th cut, to 0.062 / 0.062 / 0.062 mg (25%)
Week 55: Make 29th cut, to 0

Preliminary Information – Subject to Change

Disclaimer: This pamphlet does not provide patient medical advice. It is provided for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Example 2: Alprazolam with transition to diazepam; severe case (but far from the most severe)
Patient taking 1 mg alprazolam three times per day for 2 years. Baseline symptoms and severity noted.
Patient asks for gentle taper. After reviewing two different benzodiazepine equivalency calculators, substitute
14 mg diazepam per 1 mg alprazolam, using the following table (adapted from Ashton[8]).

<table>
<thead>
<tr>
<th>Morning</th>
<th>Midday/Afternoon</th>
<th>Evening/Night</th>
<th>Daily Diazepam Equivalent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td>alprazolam 1mg</td>
<td>alprazolam 1mg</td>
<td>alprazolam 0.5mg diazepam 7mg</td>
</tr>
<tr>
<td>Day 8</td>
<td>alprazolam 1mg</td>
<td>alprazolam 0.5mg</td>
<td>alprazolam 0.5mg diazepam 7mg</td>
</tr>
<tr>
<td>Day 15</td>
<td>alprazolam 0.5mg</td>
<td>alprazolam 0.5mg</td>
<td>alprazolam 0.5mg diazepam 7mg</td>
</tr>
</tbody>
</table>

Day 17: Patient complains of significant increase in symptoms. Increase ratio to 16 mg diazepam per 1 mg alprazolam.

<table>
<thead>
<tr>
<th>Morning</th>
<th>Midday/Afternoon</th>
<th>Evening/Night</th>
<th>Daily Diazepam Equivalent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 17</td>
<td>alprazolam 0.5mg</td>
<td>alprazolam 0.5mg</td>
<td>alprazolam 0.5mg diazepam 8mg</td>
</tr>
<tr>
<td>Week 4</td>
<td>alprazolam 0.5mg</td>
<td>alprazolam 0.5mg</td>
<td>diazepam 20mg</td>
</tr>
<tr>
<td>Week 5</td>
<td>alprazolam 0.5mg</td>
<td>-</td>
<td>diazepam 40mg</td>
</tr>
<tr>
<td>Week 6</td>
<td>-</td>
<td>-</td>
<td>diazepam 48mg</td>
</tr>
</tbody>
</table>

Week 7: Make first cut, to 45 mg (6.3%)
Week 8: Significant symptoms noted. Hold for an extra week. Symptoms return to baseline. Reduce cut to 2 mg.
Week 9: Make 2nd cut, to 43 mg (4.4%)
Week 10: Make 3rd cut, to 41 mg (4.6%)
...
Week 15: Make 8th cut, to 31 mg (6.1%)
Week 16: Significant symptoms noted. Hold for extra week, decrease cut to 1 mg
Week 17: Symptoms return to baseline. Make 9th cut, to 30 mg (3.3%)
...
Week 30: Make 22nd cut, to 17 mg (5.6%)
Week 31: Significant symptoms noted. Hold for extra week, decrease cut to 0.5 mg
Week 32: Symptoms return to baseline. Make 23rd cut, to 16.5 mg (2.9%)
...
Week 46: Make 41st cut, to 9.5 mg (5%)
Week 47: Significant symptoms noted. Hold for extra week, Decrease cut to 0.3 mg by using Intensol (0.5 mg is ¼ of the smallest available tablet, and it is unsafe to cut less than ¼)
Week 48: Symptoms return to baseline. Make 42nd cut, to 9.2 mg (3.2%)
...
Week 60: Make 54th cut, to 5.6 mg (5.1%)
Week 61: Significant symptoms noted. Hold for extra week, Decrease cut to 0.2 mg
Week 62: Symptoms return to baseline. Make 55th cut, to 5.4 mg (3.4%)
...
Week 70: Make 63rd cut, to 3.8 mg (5%)
Week 71: Significant symptoms noted. Hold for extra week, decrease cut to 0.1 mg
Week 72: Symptoms return to baseline. Make 64th cut, to 3.7 mg (2.6%)
...
Week 90: Make 82nd cut, to 1.7 mg (5.6%)

Preliminary Information – Subject to Change

Disclaimer: This pamphlet does not provide patient medical advice. It is provided for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Week 91: Significant symptoms noted. Hold for extra week, decrease cut to 0.05 mg by using Liquid Oral
Week 92: Symptoms return to baseline. Make 83rd cut, to 1.65 mg (2.9%)
...
Week 107: Make 98th cut, to 0.9 mg (5.6%)
Week 108: Significant symptoms noted. Hold for extra week, decrease cut to 0.03 mg
Week 109: Symptoms return to baseline. Make 99th cut, to 0.87 mg (3.3%)
...
Week 120: Make 110th cut, to 0.54 mg (5.3%)
Week 121: Significant symptoms noted. Hold for extra week, decrease cut to 0.02 mg
Week 122: Symptoms to baseline. Make 111th cut, to 0.52 mg (3.7%)
...
Week 133: Make 122nd cut, to 0.3 mg (6.3%)
Week 140: Significant symptoms noted. Hold for extra week, increase duration to 2 weeks.
Week 141: Symptoms to baseline. Make 123rd cut, to 0.28 mg (6.7%)
Week 143: Make 124th cut, to 0.26 mg (7.1%)
...
Week 149: Make 127th cut, to 0.2 mg (9.1%)
Week 151: Significant symptoms noted. Hold for extra week, increase duration to 3 weeks
Week 152: Symptoms to baseline. Make 128th cut, to 0.18 mg (10%)
Week 155: Significant symptoms noted. Hold until symptoms to baseline, make 129th cut, to 0.1 mg (47%)
Week 158+: Hold until symptoms to baseline, make 130th cut, to 0
4. References


[3] Pubchem


[7] Formulations already exist and are available in other countries:
   a. Roche manufacturers a 2.5mg/mL formulation that contains API, propylene glycol, glacial acetic acid, saccharin sodium, peach flavor, and brilliant blue.
   b. Iraqi pharmacists developed a 2.5mg/mL formulation. Abas et al. (2016). Full Article
   c. Two specialty pharmacies in the UK (Thame and Rosemont) manufacture a 0.1mg/mL solution. The Thame formulation uses API, ethanol (96%), and medium chain triglycerides. The Rosemont formulation uses API, ethanol (96%), medium chain triglycerides, saccharin, and levomenthol.

[8] Ashton, H Benzodiazepines: How They Work And How To Withdraw August 2002 Full article

5. Other BZD Compounding References


This publication was produced and distributed by The Alliance for Benzodiazepine Best Practices, a non-profit 501(c)(3) tax-exempt corporation of researchers and medical professionals whose mission is to make evidence-based improvements to the prescribing of benzodiazepines and Z-drugs.

Preliminary Information – Subject to Change

Disclaimer: This pamphlet does not provide patient medical advice. It is provided for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.